Rilzabrutinib + Placebo + Glucocorticoid
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Immunoglobulin G4 Related Disease
Conditions
Immunoglobulin G4 Related Disease
Trial Timeline
Sep 26, 2025 → Dec 25, 2030
NCT ID
NCT07190196About Rilzabrutinib + Placebo + Glucocorticoid
Rilzabrutinib + Placebo + Glucocorticoid is a phase 3 stage product being developed by Sanofi for Immunoglobulin G4 Related Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07190196. Target conditions include Immunoglobulin G4 Related Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07190196 | Phase 3 | Recruiting |
Competing Products
11 competing products in Immunoglobulin G4 Related Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ABBV-383 (Etentamig) | AbbVie | Phase 1/2 | 41 |
| zigakibart | Novartis | Phase 2 | 52 |
| iptacopan | Novartis | Phase 3 | 77 |
| CCX168 | Amgen | Phase 2 | 51 |
| Inebilizumab | Amgen | Phase 2 | 51 |
| rilzabrutinib + Glucocorticoids | Sanofi | Phase 2 | 51 |
| Felzartamab | Biogen | Phase 2 | 49 |
| Felzartamab + Placebo | Biogen | Phase 3 | 74 |
| Sparsentan | Travere Therapeutics | Phase 2 | 47 |
| Sparsentan | Travere Therapeutics | Phase 2 | 47 |
| sparsentan + irbesartan + Dapagliflozin | Travere Therapeutics | Phase 3 | 72 |